New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > Sarcoma

Sarcoma Regimens



Desmoid fibromatosis Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
Desmoid fibromatosis - metHOTREXATe and vinBLASTine
265691000210100
1.0.0
17/09/2023
Desmoid fibromatosis - metHOTREXATe and vinORELBine
264721000210107
1.0.0
02/07/2023

Giant Cell tumour of bone Regimens


Published

Name
Id
Version
Date
Giant Cell tumour of bone - denosumab
264671000210103
1.0.0
02/07/2023

Sarcoma Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SAR Advanced/Metastatic - pembrolizumab Q6W [flat dosing]
264701000210104
1.0.0
02/07/2023
SAR Advanced - pembrolizumab Q3W [flat dosing]
264711000210102
1.0.0
02/07/2023
SAR Advanced - pembrolizumab Q3W [weight-based dosing]
264681000210101
1.0.0
02/07/2023
SAR Angiosarcoma Advanced - PACLItaxel
264691000210104
1.0.0
02/07/2023
SAR Kaposi Sarcoma - pegylated liposomal DOXOrubicin hydrochloride
264651000210106
1.0.0
02/07/2023

Ewing Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SAR Ewing sarcoma Relapsed - CYCLOPHOSPHamide and topotecan
265561000210106
1.0.0
17/09/2023
SAR Ewing sarcoma Relapsed - irinotecan and temozolomide
264731000210109
1.0.0
02/07/2023
SAR Ewing sarcoma - VAC, VC and IE [Q2W]
components ▾
312241000210108
1.0.0
02/04/2024
VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide]
312251000210106
0.0.9
IE [IFOSFamide and etoposide]
265621000210103
0.0.11
VC [vinCRISTine and CYCLOPHOSPHamide]
265631000210101
0.0.5
SAR Ewing sarcoma - VAC, VC and IE [Q3W]
components ▾
312131000210107
1.0.0
02/04/2024
VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide]
312141000210104
0.0.17
IE [IFOSFamide and etoposide]
312111000210100
0.0.9
VC [vinCRISTine and CYCLOPHOSPHamide]
312121000210105
0.0.4
SAR Ewing sarcoma - VDC, VC and IE [Q2W]
components ▾
497041000210106
1.0.0
13/03/2025
VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSHamide]
497051000210109
0.0.10
IE [IFOSFamide and etoposide]
265621000210103
0.0.11
VC [vinCRISTine and CYCLOPHOSPHamide]
265631000210101
0.0.5
SAR Ewing sarcoma - VDC, VC and IE [Q3W]
components ▾
312091000210109
1.0.0
02/04/2024
VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide]
312101000210102
0.0.10
IE [IFOSFamide and etoposide]
312111000210100
0.0.9
VC [vinCRISTine and CYCLOPHOSPHamide]
312121000210105
0.0.4
SAR Ewing sarcoma - VDC with dexrazoxane, VC and IE [Q2W]
components ▾
265601000210106
1.0.0
17/09/2023
VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] with dexrazoxane
265611000210108
0.0.11
IE [IFOSFamide and etoposide]
265621000210103
0.0.11
VC [vinCRISTine and CYCLOPHOSPHamide]
265631000210101
0.0.5

Osteosarcoma Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SAR Osteosarcoma Advanced - DOXOrubicin [1-day dosing] and cISplatin
265571000210100
1.0.0
17/09/2023
SAR Osteosarcoma Advanced - DOXOrubicin [3-day split dosing] and cISplatin
265541000210105
1.0.0
17/09/2023
SAR Osteosarcoma - MAP [metHOTREXATe, DOXOrubicin and cISplatin]
components ▾
312061000210104
1.0.0
02/04/2024
Part 1: MAP [metHOTREXATe, DOXOrubicin and cISplatin]
312071000210105
0.0.22
Part 2: MA [metHOTREXATe and DOXOrubicin]
312081000210107
0.0.14

Rhabdomyosarcoma Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SAR Rhabdomyosarcoma Relapsed - VIT [vinCRISTine, irinotecan and temozolomide]
265551000210108
1.0.0
17/09/2023
SAR Rhabdomyosarcoma - VAC, VC, vinCRISTine and VI [ARST0531] [intermediate risk]
components ▾
497061000210107
1.0.0
13/03/2025
ARST0531 [intermediate risk] - VAC + VV [vinCRISTine days 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide]
497071000210101
0.0.7
ARST0531 [intermediate risk] - V, Irin + VV [vinCRISTine days 1, 8 and 15 and irinotecan]
497081000210104
0.0.6
ARST0531 [intermediate risk] - VC + VV [vinCRISTine days 1, 8 and 15 and CYCLOPHOSPHamde]
497091000210102
0.0.7
ARST0531 [intermediate risk] - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamde]
497101000210109
0.0.5
ARST0531 [intermediate risk] - V, Irin + V [vinCRISTine days 1 and 8 and irinotecan]
497111000210106
0.0.6
SAR Rhabdomyosarcoma - vinCRISTine, daCTINomycin and CYCLOPHOSPHamide [ARST0331] [low risk]
components ▾
497121000210101
1.0.0
13/03/2025
ARST0331 [low risk] - VAC + VV [vinCRISTine days 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide]
497131000210104
0.0.6
ARST0331 [low risk] - AC [daCTINomycin and CYCLOPHOSPHamide]
497141000210107
0.0.5
ARST0331 [low risk] - VA + VV [vinCRISTine days 1, 8 and 15, daCTINomycin] WITHOUT radiotherapy
497151000210105
0.0.6
ARST0331 [low risk] - VA + VV [vinCRISTine days 1, 8 and 15, daCTINomycin] WITH radiotherapy
497161000210108
0.0.5
ARST0331 [low risk] - A [daCTINomycin]
497171000210102
0.0.5
SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk]
components ▾
312151000210101
1.0.0
02/04/2024
ARST0431 [high risk] - V, Irin + VV [vinCRISTine days 1, 8 and 15 and irinotecan]
312161000210103
0.0.12
ARST0431 [high risk] - V, Irin + V [vinCRISTine days 1 and 8 and irinotecan]
312171000210109
0.0.11
ARST0431 [high risk] - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q2W]
312181000210106
0.0.12
ARST0431 [high risk] - IE [IFOSFamide and etoposide] [Q2W]
312191000210108
0.0.2
ARST0431 [high risk] - IE [IFOSFamide and etoposide] [Q3W]
312201000210105
0.0.2
ARST0431 [high risk] - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q3W]
312211000210107
0.0.3
ARST0431 [high risk] - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide]
312221000210102
0.0.4
ARST0431 [high risk] - VAC + VV [vinCRISTine days 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide]
312231000210100
0.0.6

STS Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SAR STS Advanced - DOXOrubicin
264661000210109
1.0.0
02/07/2023
SAR STS Advanced - DOXOrubicin and IFOSFamide 20/2000
265581000210103
1.0.0
17/09/2023
SAR STS Advanced - DOXOrubicin and IFOSFamide 25/3000
265591000210101
1.0.0
17/09/2023
SAR STS Advanced - IFOSFamide [3-day]
265641000210109
1.0.0
17/09/2023
SAR STS Advanced - pAZOPanib
265651000210107
1.0.0
17/09/2023
SAR STS Advanced - trabectedin
265661000210105
1.0.0
17/09/2023
SAR STS - IFOSFamide and DOXOrubicin [ARST0332] [intermediate and high risk]
components ▾
497181000210100
1.0.0
13/03/2025
ARST0332 [intermediate and high risk] - ID [IFOSFamide and DOXOrubicin]
497191000210103
0.0.13
ARST0332 [intermediate and high risk] - I [IFOSFamide]
497201000210101
0.0.10
ARST0332 [intermediate and high risk] - D [DOXOrubicin]
497211000210104
0.0.7
SAR STS Metastatic - DOCEtaxel and gemcitabine 675 [GeDDis]
265671000210104
1.0.0
17/09/2023
SAR STS Metastatic - DOCEtaxel and gemcitabine 900
265681000210102
1.0.0
17/09/2023